{"id":"NCT03308799","sponsor":"MC2 Therapeutics","briefTitle":"A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream","officialTitle":"A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-03","primaryCompletion":"2018-06-08","completion":"2018-06-08","firstPosted":"2017-10-13","resultsPosted":"2019-10-29","lastUpdate":"2024-12-09"},"enrollment":794,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis Vulgaris"],"interventions":[{"type":"DRUG","name":"MC2-01 cream","otherNames":[]},{"type":"DRUG","name":"Cal/BDP combination","otherNames":[]},{"type":"DRUG","name":"Cream vehicle","otherNames":[]}],"arms":[{"label":"MC2-01 Cream","type":"EXPERIMENTAL"},{"label":"Cal/BDP combination","type":"ACTIVE_COMPARATOR"},{"label":"Cream vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.","primaryOutcome":{"measure":"Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8","timeFrame":"Baseline and 8 weeks","effectByArm":[{"arm":"MC2-01 Cream","deltaMin":121,"sd":null},{"arm":"CAL/BDP Combination","deltaMin":67,"sd":null},{"arm":"Vehicle","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["40274711","37490268","34648147","33852251"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":342},"commonTop":[]}}